Year: 2016
Language: Russian
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).
Listen to this 90-minute webinar presented on March 8, 2022, to learn about women and girls with bleeding disorders. The
A summary of discussions held at the Eleventh WFH Global Forum on Research and Treatment Products for Bleeding Disorders which
Listen to this 90-minute webinar presented on September 1, 2021 to learn about advocating for better care using the ASH
Listen to this 2-hour webinar presented on December 16, 2021, to learn about global topics related to bleeding disorders, with
This module was presented by Mohsena Olath-Carramtally at the Virtual Workshop for Psychosocial Professionals in Europe on June 23, 2021.
This module was presented by Susan Cutter at the Virtual Workshop for Psychosocial Professionals in Europe on June 23, 2021.